Initial implementation of PrEP in Zambia: health policy development and service delivery scale-up by Claassen, Cassidy W et al.
1Claassen CW, et al. BMJ Open 2021;11:e047017. doi:10.1136/bmjopen-2020-047017
Open access 
Initial implementation of PrEP in 
Zambia: health policy development and 
service delivery scale- up
Cassidy W. Claassen   ,1,2,3 Daliso Mumba,4,5 Mwansa Njelesani,6 
Derrick Nyimbili,7 Linah K Mwango,8 Mundia Mwitumwa,2,3 Ellen Mubanga,4 
Lloyd B. Mulenga,2,3,5 Tina Chisenga,5 Brooke E. Nichols   ,9,10 
Cheryl Hendrickson   ,10 Lastone Chitembo,11 Jackson Okuku,12 Heidi O'Bra13
To cite: Claassen CW, 
Mumba D, Njelesani M, et al.  
Initial implementation of 
PrEP in Zambia: health policy 
development and service 
delivery scale- up. BMJ Open 
2021;11:e047017. doi:10.1136/
bmjopen-2020-047017
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
047017).
Received 07 December 2020
Accepted 10 June 2021
For numbered affiliations see 
end of article.
Correspondence to
Dr Cassidy W. Claassen;  
 cclaassen@ ihv. umaryland. edu
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Introduction Daily pre- exposure prophylaxis (PrEP) 
for HIV prevention is highly effective, but not yet widely 
deployed in sub- Saharan Africa. We describe how Zambia 
developed PrEP health policy and then successfully 
implemented national PrEP service delivery.
Policy development Zambia introduced PrEP as a key 
strategy for HIV prevention in 2016, and established 
a National PrEP Task Force to lead policy advocacy 
and development. The Task Force was composed of 
government representatives, regulatory agencies, 
international donors, implementation partners and civil 
society organisations. Following an implementation pilot, 
PrEP was rolled out nationally using risk- based criteria 
alongside a national HIV prevention campaign.
National Scale-up In the first year of implementation, 
ending September 2018, 3626 persons initiated PrEP. 
By September 2019, the number of people starting PrEP 
increased by over sixfold to 23 327 persons at 728 sites 
across all ten Zambian provinces. In the first 2 years, 
26 953 clients initiated PrEP in Zambia, of whom 31% 
were from key and priority populations. Continuation 
remains low at 25% and 11% at 6 and 12 months, 
respectively.
Lessons learnt Risk- based criteria for PrEP ensures 
access to those most in need of HIV prevention. Healthcare 
worker training in PrEP service delivery and health needs 
of key and priority populations is crucial. PrEP expansion 
into primary healthcare clinics and community education is 
required to reach full potential. Additional work is needed 
to understand and address low PrEP continuation. Finally, 
a task force of key stakeholders can rapidly develop and 
implement health policy, which may serve as a model for 
countries seeking to implement PrEP.
INTRODUCTION
Daily pre- exposure prophylaxis (PrEP) with 
tenofovir disoproxil fumarate and emtricit-
abine for the prevention of HIV infection 
is a highly effective prevention tool, recom-
mended for persons at substantial risk of HIV 
infection by WHO since 2015.1 PrEP effective-
ness is highly correlated to adherence,2–6 with 
studies showing that PrEP is most effective 
when adherence is >70%0.7 PrEP has the 
potential to limit HIV acquisition among 
at- risk populations, including those who 
may not be able to negotiate condom usage 
or who engage in high- risk activities. PrEP 
can be taken discreetly, it offers high rates 
of protection, and does not require negoti-
ation with partners, unlike barrier methods 
and microbicide gels.8 9 PrEP is also associ-
ated with few safety risks, and there is limited 
evidence of behavioural risk compensation.7 
Despite these promising results, PrEP roll- out 
has been slow in sub- Saharan Africa with only 
a handful of countries implementing large 
scale national PrEP programmes, including 
South Africa, Kenya, Uganda, Zimbabwe and 
Zambia.10
Initial PrEP demonstration implementa-
tion projects have shown high uptake among 
serodiscordant couples (SDCs),11 12 adoles-
cent girls and young women (AGYW),13 14 
female sex workers (FSWs)15–17 and men who 
have sex with men (MSM).18 19 Interest in, and 
Strengths and limitations of this study
 ► This study documents how the Zambian pre- 
exposure prophylaxis (PrEP) Task Force, consisting 
of health professionals from government, donors 
and implementing partners, rapidly drafted and im-
plemented national PrEP health policy.
 ► This study describes the national implementation 
and scale up of PrEP to >700 health facilities and 
nearly 27 000 clients in 2 years.
 ► PrEP service delivery is examined by key population 
type as well as mapped to population density and 
HIV prevalence.
 ► A limitation of this study is the use of aggregate data; 
thus it does not include patient- level data for better 
understanding of PrEP uptake and continuation.
 ► The Zambia PrEP health policy development model 
may be useful to other countries seeking to imple-
ment PrEP.
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uptake of, PrEP is high but PrEP continuation remains a 
challenge in many groups, particularly AGYW. Successful 
national PrEP programmes in Africa have invested in 
creating PrEP awareness and demand via mass media and 
community health talks, have streamlined PrEP delivery 
via not only ART clinics but also drop- in centres for key 
populations (KPs) and DREAMS (Determined, Resil-
ient, Empowered, AIDS- free, Mentored, Safe) centres for 
AGYW, and have built PrEP capacity among healthcare 
workers (HCWs) via trainings and mentorship. Chal-
lenges in PrEP programming persist, including the need 
to improve PrEP access, streamline PrEP delivery models, 
increase HCWs trained in PrEP and finally increase PrEP 
continuation.10
Zambia’s HIV epidemic is generalised, with a persistently 
high prevalence of 12.0% and annual incidence of 0.61% 
among adults 15–59 years old.20 Concentrated pockets of 
high HIV transmission disproportionately affect popu-
lations who face substantial psychosocial and structural 
barriers to accessing health services and continue to drive 
epidemic transmission. These include SDCs; AGYW; 
FSW and their clients; MSM21; transgendered (TG) indi-
viduals22 and high- risk men, particularly those under 
30, engaged in migrant work (eg, truck drivers,23 cane 
cutters24 or in prison).25 26 These groups have a higher HIV 
prevalence compared with the general population, and 
would benefit the most from HIV prevention methods, 
including biomedical interventions such as PrEP.
Beginning in 2016, Zambia introduced PrEP as a 
component of combination HIV prevention services, 
which also includes counselling, family planning, volun-
tary male medical circumcision and condom distribution. 
In this paper, we present a model of integrated health 
policy and technical service delivery accomplished by 
government agencies, donors, and implementing part-
ners for the roll- out of PrEP in Zambia. We also report 
on the current status, challenges faced, and lessons learnt 
from PrEP policy and service delivery implementation in 
Zambia.
PrEP policy and implementation
Development of PreP health policy and implementation guidelines 
in Zambia
In 2016, the Zambian Ministry of Health (MOH) adopted 
the 2015 WHO guidelines1 recommending daily oral 
PrEP for people at substantial risk of HIV infection, 
defined as HIV incidence greater than 3 per 100 person- 
years (see figure 1 for a timeline of PrEP policy and imple-
mentation). PrEP was introduced in the 2016 Zambia 
Consolidated Guidelines for Treatment and Prevention 
of HIV Infection27 and further expanded in the 2018 
version.28 In September 2017, the National PrEP Task 
Force was established, comprising key personnel from 
MOH, National HIV/AIDS/STI/TB Council, WHO, 
UNAIDS, US President’s Emergency Plan for AIDS Relief 
(PEPFAR), US Agency for International Development 
(USAID), US Centers for Disease Control and Prevention 
(CDC), PEPFAR implementing partners (IPs) and civil 
society organisations (CSOs). The Task Force’s mandate 
was to lead policy advocacy and formulate a national 
PrEP implementation framework to guide PrEP service 
delivery. The Task Force created three sub- committees: 
(1) medical/technical service delivery and monitoring 
and evaluation (M&E); (2) logistics and supply chain and 
(3) social behavioural change communication and policy 
advocacy. Within each subcommittee, technical experts 
reviewed the latest evidence and guidelines for the larger 
Task Force (table 1, next page). Additionally, the Task 
Figure 1 Timeline of PrEP policy and implementation in Zambia. PrEP, pre- exposure prophylaxis; SDC, serodiscordant 
couples; UMB, University of Maryland Baltimore; UTH, University Teaching Hospital.
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Force participated in international workshops to catalyse 
and share policy development and implementation expe-
riences across southern Africa.
The 2016 Zambian antiretroviral treatment (ART) 
guidelines recommended PrEP for SDCs and considered 
for high- risk persons, though risk was not defined. For the 
2017 ART guidelines, the Task Force considered recom-
mending PrEP for KPs. However, Zambia remains largely 
conservative on diverse sexual orientation and gender 
identity rights. To avoid stigmatising PrEP as a KP inter-
vention and to ensure access to any person at high risk for 
HIV, the Task Force adopted risk- based criteria for PrEP 
eligibility, instead of population- specific criteria (box 1).
In addition to the guidelines, MOH and the Task Force 
introduced the Implementation Framework & Guidance for 
PrEP of HIV Infection in 2018.29 This framework provides 
comprehensive clinical and programme implementa-
tion guidance on service delivery of PrEP. This included 
minimum standards for service delivery with the recom-
mendation to first implement PrEP service delivery in areas 
of HIV incidence and/or prevalence at existing ART clinics 
before scaling to community models. Required human 
resources for PrEP included nurses or clinical officers 
trained in ART who could provide PrEP, pharmacy staff for 
dispensation and counsellors and peer educators for educa-
tion and adherence counselling. The framework employs a 
people- centred approach to PrEP service delivery, empha-
sising health coverage, gender equality and health- related 
rights including accessibility, availability, acceptability and 
quality. PrEP services are clearly outlined and include guid-
ance and recommendations on:
 ► Service delivery standards, human resource needs, 
and supply chain management.
 ► Regulation of importing, marketing, and control of 
PrEP medications.
 ► PrEP indications, usage, drug interactions, side effects 
and discontinuation.
 ► Advocacy, education and demand generation 
materials.
 ► Recommended social behaviour change strategy.
 ► Documentation and M&E of PrEP service delivery.
PrEP pilot and policy implementation and service delivery roll-
out
Between October 2017 and March 2018, the University of 
Maryland Baltimore (UMB) and the University Teaching 
Hospital in Lusaka, with special permission from the 
MOH, piloted a PrEP intervention package at two public 
health facilities in Lusaka and Livingstone. The inter-
vention included community education on PrEP along-
side training of HCWs on KP sensitivity and PrEP service 
delivery. Initial results from this pilot demonstrated high 
levels of interest and uptake among users, but low PrEP 
continuation by 3 months: among 1002 clients that tested 
negative for HIV, 326 (33%) were eligible for PrEP, of 
whom 116 (36%) elected to begin PrEP; 95 (82%) of 
these clients presented for 1- month follow- up and 31 
(27%) clients for 3- month follow- up.30
The lessons learnt from this pilot were crucial to 
informing the broader national PrEP strategy. Additional 
training on community awareness and PrEP demand was 
required to ensure successful programme scale- up. To 
address this, UMB developed peer- led promotion of PrEP 
uptake through targeted messaging in KP communities, 
and also created social media platforms (WhatsApp and 
Facebook) where current and potential clients could 
discuss PrEP with mentor users and knowledgeable 
HCWs. Additionally, the pilot emphasised the need for 
expanded HCW training and community support for 
PrEP and KP- friendly services, with services provided in 
KP safe spaces by HCWs trained to provide services in 
a non- discriminatory manner. Trainings in PrEP service 
provision were extended to community health workers 
(CHWs) and peer supporters who created demand 
for PrEP and encouraged PrEP continuation. KP peer 
promoters were recruited from the KP community to 
disseminate HIV prevention and testing messages with 
a focus on the benefits of PrEP. Finally, operating hours 
at PrEP clinics were adjusted to include evenings, and 
PrEP services were provided closer to target populations 
in order to mitigate access barriers observed in the pilot 
study.
The MOH, with financial and technical support from 
PEPFAR and IPs, began the national roll- out of PrEP in 
2018. Activities ranged from policy development, health 
system strengthening, commodity procurement (labo-
ratory and drug requirements), service delivery (staff, 
training/mentorship, etc), M&E and demand creation. 
Concurrently, in early 2018, the Task Force set targets 
for national PrEP roll- out, focusing on facilities offering 
ART in high- burden areas. PEPFAR partners developed 
and implemented differentiated service delivery (DSD) 
models to serve the unique needs of each targeted popu-
lation for early PrEP roll- out. To identify high- risk areas in 
the community hotspot mapping was conducted. KP safe 
spaces were set up where PrEP could be provided to MSM 
and FSWs. Nearby health facilities supported these safe 
spaces with HCW staff trained in PrEP service delivery as 
well as KP sensitivity, safety and security.
Box 1 Zambia PrEP Risk- based eligibility criteria 2018
Persons at substantial risk for HIV infection, defined as engaging in one 
or more of the following activities within the last 6 months:
 ► Vaginal/anal intercourse without condoms with more than one 
partner.
 ► Sexually active with a partner who is known to be HIV- positive or at 
substantial risk of being HIV- positive.
 ► Sexually active with an HIV- positive partner who is not on effec-
tive treatment (defined as on cART for <6 months or not virally 
suppressed).
 ► History of STI.
 ► History of PEP use.
 ► Sharing injection material or equipment.
cART, combined antiretroviral therapy; PrEP, pre- exposure prophylaxis; 
PEP, post- exposure prophylaxis; STI, sexually transmitted infection.
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For all models of service provision, IPs supported 
the MOH to train clinicians, nurses, CHWs, and peer 
supporters in PrEP service delivery, demand creation, 
and M&E.
To aid in public education and demand creation, the 
Zambia Ending AIDS national HIV prevention campaign 
was implemented in 2019, with technical support from 
JSI/USAID DISCOVER- Health. The campaign provided 
information on HIV prevention with a key focus on PrEP, 
and disseminated information on PrEP via social media 
and cellular phone text messages. The campaign was 
driven by findings from a human- centred design study 
that found: (1) low awareness of PrEP, including among 
HCWs, with safety and tolerability concerns; (2) higher 
awareness among youth and KPs, who viewed PrEP 
favourably for high- risk situations; (3) AGYW saw PrEP 
as a way to exercise control over their own HIV preven-
tion, (4) older men viewed PrEP as a way to have safer sex 
without a condom; (5) young people concerned about 
parents finding out they were on ARVs; (6) high levels of 
judgmental and discriminatory attitudes among HCWs.
These findings were used to design the PrEP subcam-
paign in the broader Zambia Ending AIDS campaign. 
The key tenets of the campaign include sex positivity (ie, 
sex without judgement or stigma) and addressing low risk 
perception; PrEP and combination HIV prevention, as 
well as a focus on men’s health and male- specific health 
programming; education of HCWs as caring providers 
of sexual health; and, enhanced health communication 
tools (figure 2).
PrEP programme M&E
In accordance with the national framework M&E guid-
ance, aggregated PrEP service delivery data including 
age, sex, KP type and geographical reach are reported 
semi- annually by IPs into the PEPFAR reporting database 
(DATIM). The PEPFAR fiscal year (FY) is from October 
1 to September 30 each year. To evaluate early PrEP 
programme scale- up, we analysed deidentified aggre-
gate PrEP service delivery data from DATIM, with ethical 
clearance granted by ERES, NHRA, UMB and CDC. Data 
included sex, age, KP type, rates of uptake and follow- up 
at each clinical visit. We also conducted geo- mapping to 
overlay provision of PrEP services with population density 
and HIV prevalence.
Patient and public involvement
Only aggregate patient data was used in this study. Patient 
advocates and civil society representatives formed part of 
the National PrEP Task Force and participated in drafting 
policy and setting the national policy agenda. Key results 
about PrEP have been routinely disseminated to the 
public at national meetings and conferences and other 
venues.
Figure 2 Selected materials from Zambia ending AIDS campaign. PrEP, pre- exposure prophylaxis.




Between October 2017 and September 2018 (PEPFAR FY 
18), a total of 3603 persons initiated PrEP, with partic-
ular focus on populations most at risk of contracting 
HIV, namely AGYW (n=1272, 34%), FSWs (n=312, 9%) 
and MSM (n=92, 3%). During this period, nearly half of 
all PrEP initiates were KPs or priority populations (PPs) 
(ie, FSW, MSM, TG, PWID, AGYW): 52% from April to 
September 2017, 48% from October 2017 to March 2018, 
and 46% from April to September 2018, with the other 
half being SDCs or general population (figure 3). During 
this first year of PrEP provision, prior to the national 
launch, programme scale was limited and IPs largely 
focused on KPs/PPs.
National HIV prevention campaign
Between April 2019—when the Zambia Ending AIDS 
campaign was launched—and September 2019, over 
4.5 million people were reached on social media with 
campaign messaging. PrEP advertisements were broad-
cast in six major Zambian languages over 90 million 
times on 22 national and community radio and television 
stations. From January to September 2019, 140 933 people 
accessed the national toll- free Unstructured Supplemen-
tary Service Data (USSD) code for information about 
PrEP. Of these, 27 889 requested information about the 
nearest PrEP facility. People tended to access the USSD 
code when there was high rotation of the PrEP adverts 
on radio, highlighting the importance of sustained PrEP 
sensitisation (figure 4).
Full scale-up
By March 2019, access and availability of PrEP had 
substantially increased, with services available across all 
ten provinces in 340 sites (of approximately 2000 ART- 
providing sites across Zambia). By September 2019, 
PrEP services delivery had expanded to 728 sites and 
included health facilities, health outreach posts and 
non- traditional sites such as PEPFAR DREAMS Centres 
(community centres for prevention services for AGYW), 
police camps, prisons, markets and universities. The data 
did not allow for breakdown of clients served per facility; 
however, service delivery mapping indicates that PrEP is 
currently provided in the areas of greatest population 
density where the HIV burden is most concentrated 
(figure 5).
Both the HIV prevention campaign and the increase 
in number of sites offering PrEP has led to a substantial 
increase in the number of people initiating PrEP. From 
April–September 2018 to October 2018–March 2019, 
the number of PrEP initiates more than doubled, from 
3248 to 7018, and this increased an additional two- fold to 
16 309 new initiates in April–September 2019 (figure 3). 
By September 2019, a total of 26 953 clients had initiated 
PrEP.
There was also a concurrent increase in KPs accessing 
PrEP; new FSW initiates increased fourfold (248 to 1062) 
and MSM initiates increased ninefold (55–504) in the 
same time period. Interestingly, despite this increase in 
KPs accessing PrEP, the proportion of KPs as a total of 
all PrEP users has declined, showing the relative broad 
uptake and appeal of PrEP among the general popula-
tion. From April to September 2019, just 26% of all new 
PrEP initiates were KPs, a significant decline from 46% 
just a year prior. This shift in PrEP user- type may result 
in continued increased demand for PrEP and PrEP 
normalisation, and is in line with the aims of the national 
HIV prevention campaign. This increased proportion of 
non- KP PrEP users highlights the Zambian PrEP policy’s 
success in not targeting KPs alone, but making PrEP avail-
able to any individual at significant risk of acquiring HIV.
Figure 3 Total number of new PrEP initiates by population 
type since beginning of Zambian PrEP programme, in half- 
year increments. AGYW, adolescent girls and young women; 
FSW, female sex workers; KP, key population; MSM, men 
who have sex with men; PWID, people who inject drugs; TG, 
transgende.
Figure 4 PrEP information access correlates to ending 
AIDS campaign media broadcasts. Snapshots of national 
radio listeners and TV broadcasts over a 6- month period in 
2019, with overlay of frequency of USSD PrEP code being 
accessed. USSD PrEP codes track closely with Zambia 
ending AIDS campaign media broadcasts. PrEP, pre- 
exposure prophylaxis.
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PrEP continuation
Continuation data are not consistently collected and 
reported in the national system or in DATIM. However, 
in the UMB pilot study, among 116 clients who enrolled 
on PrEP, 95 (82%) returned at 1 month and 31 (27%) 
returned at 3 months. PrEP continuation at 3 months 
was highest for SDCs (42%), then TG (33%), then MSM 
(23%) and lowest among FSWs (21%).30
JSI conducted a snapshot analysis of data at their 
supported sites for persons initiated on PrEP from 
January 2018 to April 2020, whereby only those on PrEP 
for a certain duration of time were included in the corre-
sponding denominator. In this analysis, 42% (6358/15 
110) of persons who had been initiated on PrEP returned 
at 1 month for PrEP refills. Persistence at 3 months was 
35% (4709/13 383), 6 months 25% (2507/10 199), 9 
months 13% (980/7413) and by 12 months was only 11% 
(570/5246).
DISCUSSION
Between 2016 and 2018, Zambia developed health policy 
and a national framework to support the introduction 
and national scale- up of PrEP to those most at risk of HIV 
infection. In the first year, initial guidelines were devel-
oped and pilot implementations were conducted, serving 
less than 4000 people. In year two, more expansive, risk- 
based criteria were adopted, and scale- up led to a sixfold 
increase with over 23 000 persons starting PrEP. The 
introduction of PrEP is reflective of a collaborative effort 
from a multidisciplinary task force comprised of the 
Zambian government, PEPFAR, WHO, UNAIDS, PEPFAR 
IPs and CSOs with the mandate to rapidly develop the 
national strategy and improve access and delivery of PrEP 
to at- risk groups. Mapping of PrEP services to HIV prev-
alence demonstrates that PrEP services are largely being 
provided where there is greatest need. Provision of DSD 
models such as PrEP service delivery in community safe 
Figure 5 Geographic distribution of HIV PrEP sites in Zambia in 2019. Panel (A) Zambian government health facilities providing 
PrEP in orange, overlaying HIV prevalence by Province. Panel (B) Zambian government health facilities providing PrEP in 
orange, overlaying population density by Province. PrEP, pre- exposure prophylaxis.
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spaces was found to support PrEP uptake among KPs.31 
Further support by IPs is needed to ensure that PrEP 
is available to all populations at substantial risk of HIV, 
including those in rural areas. Further research and 
innovative service delivery models are needed to address 
barriers to access and continuation of PrEP services for 
those who continue to be at risk of HIV infection.
While Zambia was able to achieve rapid roll- out and 
implementation of PrEP, estimates of continuation on 
PrEP remains low. It should be noted that these esti-
mates are partner- specific and more targeted studies are 
needed. However, when compared with other real- world 
implementations in Africa, 25% continuation at 6 months 
and 11% at 12 months is in line with other studies: the 
Kenya demo project found 6 months continuation rates 
of 15% among MSM, 14% among FSWs, and 10% among 
women,32 while the TAPS study found 30% continuation 
at 6 months among South African FSWs.17
Further understanding the drivers of PrEP discontin-
uation is needed to improve uptake and continuation of 
PrEP for those at continued risk of HIV infection, as well 
as ongoing community education and demand genera-
tion. Avenues to reduce PrEP stigma and discrimination 
should be explored, such as using different branding for 
PrEP drugs versus ARVs. For PrEP to reach its full poten-
tial it needs to be available at all primary health facilities 
and through DSD models. Finally, augmenting advocacy 
efforts may help increase PrEP access in contexts where 
KPs are largely stigmatised.
Limitations of this study include the reliance on aggre-
gate data and the lack of patient perspective. Patient- level 
analyses are needed to understand who stays on PrEP 
and who does not, while qualitative studies are needed to 
illuminate why certain people take up PrEP while others 
decline, as well as reasons for adherence or discontinua-
tion. Further study in these areas is critical to ensure that 
PrEP is provided to those who can most benefit from it.
The PrEP roll- out in Zambia can be compared with 
the successful PrEP scale up effort in Kenya.33 Similar 
to Zambia, Kenya established a PrEP Technical Working 
Group; however they opted for six thematic subcommit-
tees instead of three. Kenya also achieved quick roll- out, 
from launching guidelines in July 2016 to launching 
national PrEP scale- up in May 2017. Kenya similarly 
recognised the strategic importance of partnerships 
among government, IPs, and CSOs. They also high-
lighted the need for training of HCWs, the importance 
of demand creation and social marketing, community- led 
programmes, PrEP integration into commodity manage-
ment systems, and the importance of engaging with MOH 
from the outset.
A unique element of Zambia’s PrEP scale- up was 
the decision to use risk- based criteria as opposed to 
population- based criteria. It has been argued that national 
PrEP programmes often follow a certain sequence, the 
‘first wave’ being PrEP delivery for KPs followed by a 
‘second wave’ for PPs, especially AGYW.34 By eliminating 
KP/PP- typology from the eligibility criteria, we ensure 
that all persons at risk for HIV can access PrEP, regard-
less of how they identify. This is critical in the setting of 
a generalised epidemic such as Zambia, where multiple 
groups of persons are at ongoing risk. Given that certain 
KPs are at high risk of stigmatisation, by not associating 
the PrEP programme with KPs we avoided issues around 
PrEP being used as a marker of certain activities.
However, a potential drawback of this approach is that 
it risks not reaching groups most at risk. Indeed initial 
uptake of PrEP in Zambia included a high proportion 
of general population (including SDCs) compared with 
KPs and PPs. This mirrors the uptake in both Kenya33 and 
Uganda35 both of which saw over 60% of PrEP being taken 
up by general population and SDCs. This may be due to 
broader inclusion criteria which may also be related to low 
continuation rate as we may not have reached the most 
at- risk persons who are likely to continue. This type of 
broad approach may also reduce overall cost- effectiveness 
of the PrEP programme more generally. However, though 
Zambia employed a risk- based approach, there was 
substantial investment in KP- specific programming to 
ensure uptake by those most at risk of infection.
Another advantage of a risk- based approach is that 
it allows for evaluation of ‘seasons of risk’ with persons 
starting and stopping PrEP based on an objective assess-
ment of their risk at any point in time. This data can also 
be used to compare different strategies for PrEP roll- out, 
using our recently developed programme evaluation 
metric, which allows for comparison of PrEP programmes 
serving KPs and PPs.36
Lessons learnt
We present an example of health policy development 
that led to rapid national implementation and service 
delivery scale- up. Key elements of success included a 
firm grounding in evidence- based approaches which 
enabled a strong case for PrEP implementation; a multi-
sector, interdisciplinary task force which allowed for 
rapid advancement of policy and implementation; and a 
well- planned implementation pilot, which provided key 
lessons that informed the national scale- up. A particular 
strength of Zambia’s PrEP guidelines is the risk- based 
approach, making it an intervention available to all 
persons at risk, not just members of certain populations. 
Conducting a client- centred public awareness campaign 
is key to disseminating knowledge about PrEP and driving 
demand creation. Further detailed quantitative and quali-
tative research is needed to understand drivers of uptake, 
continuation and discontinuation. Such approaches to 
PrEP health policy development and service delivery 
implementation can serve as a model to other countries 
seeking to implement PrEP for HIV prevention.
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